• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Haemonetics Corporation (Amendment)

    2/13/24 3:28:26 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care
    Get the next $HAE alert in real time by email
    SC 13G/A 1 formsc13ga-02132024_080223.htm FORM schedule-13g


     
     


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G/A
    Under the Securities Exchange Act of 1934
    (Amendment No. 4)*


     
    HAEMONETICS CORP
    (Name of Issuer)
    Common
    (Title of Class of Securities)
    405024100
    (CUSIP Number)
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [ x ] Rule 13d-1(b)

    [   ] Rule 13d-1(c)

    [   ] Rule 13d-1(d)



    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.


    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     
     


     
    CUSIP No. 405024100
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Group LLC

        61-1591182

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  
    (b)   Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Citizenship or Place of Organization

     

        Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (5)    

    Sole Voting Power

     

        0

       (6)   

    Shared Voting Power

     

        3,390,861

       (7)   

    Sole Dispositive Power

     

        0

       (8)   

    Shared Dispositive Power

     

        3,531,181

    (9)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        3,531,181

    (10)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares     [ x ]

     

        (See Instructions)

    (11)

     

    Percent of Class Represented by Amount in Row (9)

     

        6.96%

    (12)

     

    Type of Reporting Person (See Instructions)

     

        HC


    CUSIP No. 405024100
      (1)   

    Names of Reporting Persons/ I.R.S. Identification Nos. of Above Persons (Entities Only)

     

        Neuberger Berman Investment Advisers LLC

        02-0654486

      (2)  
    Check the Appropriate Box if a Member of a Group (See Instructions)
    (a)  
    (b)   Membership in Group is Disclaimed
      (3)  

    SEC Use Only

     

      (4)  

    Citizenship or Place of Organization

     

        Delaware

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person

    With

       (5)    

    Sole Voting Power

     

        0

       (6)   

    Shared Voting Power

     

        3,368,180

       (7)   

    Sole Dispositive Power

     

        0

       (8)   

    Shared Dispositive Power

     

        3,497,296

    (9)

     

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

        3,497,296

    (10)

     

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares     [ x ]

     

        (See Instructions)

    (11)

     

    Percent of Class Represented by Amount in Row (9)

     

        6.89%

    (12)

     

    Type of Reporting Person (See Instructions)

     

        IA


    Item 1.
    (a) Name of Issuer
    HAEMONETICS CORP
    (b) Address of Issuer's Principal Executive Offices
    125 SUMMER STREET
    BOSTON, Massachusetts, 02110

    Item 2.
    (a) Name of Person Filing
    Neuberger Berman Group LLC
    Neuberger Berman Investment Advisers LLC
    (b) Address of Principal Business Office or, if none, Residence
    1290 Avenue of the Americas
    New York, NY 10104
    (c) Citizenship
    Delaware
    (d) Title of Class of Securities
    Common
    (e) CUSIP Number
    405024100

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)
    [   ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)
    [   ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [   ]
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [   ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [   ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    [   ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)
    [   ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)
    [   ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [   ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ x ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(J).

    Item 4.
    (a) Amount beneficially owned:
    3,531,181

    Neuberger Berman Trust Co N.A., Neuberger Berman Trust Co of Delaware N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC, and Neuberger Berman Investment Advisers LLC and certain affiliated persons may be deemed to beneficially own the securities covered by this report in their various fiduciary capacities by virtue of the provisions of Exchange Act Rule 13d-3. Neuberger Berman Group LLC, through its subsidiaries Neuberger Berman Investment Advisers Holdings LLC and Neuberger Trust Holdings LLC controls Neuberger Berman Trust Co N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC, Neuberger Berman Trust Co of Delaware N.A. and Neuberger Berman Investment Advisers LLC and certain affiliated persons.

    This report is not an admission that any of these entities are the beneficial owner of the securities covered by this report and each of Neuberger Berman Group LLC, Neuberger Berman Investment Advisers Holdings LLC, Neuberger Trust Holdings LLC, Neuberger Berman Trust Co N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC, Neuberger Berman Trust Co of Delaware N.A. and Neuberger Berman Investment Advisers LLC and certain affiliated persons disclaim beneficial ownership of the securities covered by this statement pursuant to Exchange Act Rule 13d-4.

    The information in this filing reports securities of the issuer that may be deemed to be beneficially owned by Neuberger Berman Group LLC, Neuberger Berman Investment Advisers Holdings LLC, Neuberger Trust Holdings LLC, Neuberger Berman Trust Co N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC, Neuberger Berman Trust Co of Delaware N.A. and Neuberger Berman Investment Advisers LLC ("NBG Filers"). The securities of the issuer, if any, that may be deemed to be beneficially owned by NB Alternatives Advisers LLC and other subsidiaries of Neuberger Berman Group LLC that are separated from the NBG Filers by an information barrier in accordance with SEC Release No. 34-39538 (January 12, 1998) are not reflected in this filing.
    (b) Percent of class:
    6.96%
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote
    0
    (ii) Shared power to vote or to direct the vote
    3,390,861
    (iii) Sole power to dispose or to direct the disposition of
    0
    (iv) Shared power to dispose or to direct the disposition of
    3,531,181

    Item 5. Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [   ]

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Neuberger Berman Group LLC and its affiliates may be deemed to be beneficial owners of securities for purposes of Exchange Act Rule 13d-3 because they or certain affiliated persons have shared power to retain, dispose of or vote the securities of unrelated clients. Neuberger Berman Group LLC or its affiliated persons do not, however, have any economic interest in the securities of those clients. The clients have the sole right to receive and the power to direct the receipt of dividends from or proceeds from the sale of such securities. Other than named in this filing, no one client has an interest of more than 5% of the issuer.

    With regard to the shares set forth under item 4(c)(ii), Neuberger Berman Group LLC may be deemed to be the beneficial owner for purposes of Rule 13d-3 because certain affiliated persons have shared power to retain, dispose of and vote the securities. In addition to the holdings of individual advisory clients, Neuberger Berman Investment Advisers LLC serves as investment manager of Neuberger Berman Group LLC's various registered mutual funds which hold such shares. The holdings belonging to clients of Neuberger Berman Trust Co N.A., Neuberger Berman Trust Co of Delaware N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC and Neuberger Berman Investment Advisers LLC are also aggregated to comprise the holdings referenced herein.

    In addition to the shares set forth under Item 4(c)(ii) for which Neuberger entities also have shared power to dispose of the shares, item 4(c)(iv) also includes shares from individual client accounts over which Neuberger Berman Investment Advisers LLC has shared power to dispose but does not have voting power over these shares. The holdings of Neuberger Berman Trust Co N.A., Neuberger Berman Trust Co of Delaware N.A., Neuberger Berman Asia Ltd., Neuberger Berman Canada ULC and Neuberger Berman Investment Advisers LLC, are also aggregated to comprise the holdings referenced herein.

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.
    N/A

    Item 8. Identification and Classification of Members of the Group.
    N/A

    Item 9. Notice of Dissolution of Group.
    N/A

    Item 10. Certification.
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


     
    SIGNATURES
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Date:   February 13, 2024
    Neuberger Berman Group LLC
    By: /s/ Brad Cetron

    Name: Brad Cetron
    Title: Managing Director
    Date:   February 13, 2024
    Neuberger Berman Investment Advisers LLC
    By: /s/ Brad Cetron

    Name: Brad Cetron
    Title: Managing Director


    Get the next $HAE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HAE

    DatePrice TargetRatingAnalyst
    2/7/2025$95.00 → $68.00Neutral → Underperform
    BofA Securities
    12/6/2024$116.00Overweight
    Analyst
    11/8/2024$120.00Outperform → Strong Buy
    Raymond James
    9/13/2024$116.00Buy
    CL King
    9/11/2024$85.00Neutral
    BofA Securities
    9/10/2024$112.00Buy
    BTIG Research
    6/12/2024$112.00Hold → Buy
    Needham
    10/13/2022$90.00Buy
    Mizuho
    More analyst ratings

    $HAE
    Financials

    Live finance-specific insights

    See more
    • Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

      Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2

      5/8/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

      BOSTON, March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. The call can be accessed via teleconference at: Q4 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.

      3/31/25 4:00:00 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website

      Financial release accessible online BOSTON, Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its third quarter fiscal year 2025, which ended December 28, 2024, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on February 6, 2025. The conference call and webcast can be accessed with the following information: Teleconference link: https://register.vevent.com/register/BIda08929a4d56464

      2/6/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

      Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2

      5/8/25 6:00:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System

      First fully absorbable, sutureless closure system designed for large-bore procedures aims to improve procedural efficiency and patient outcomes in structural heart interventions Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced European CE mark approval of the PerQseal® Elite vascular closure system, a sutureless and fully bioresorbable large-bore vessel closure device. The company plans to launch the product in select European markets this summer. Leveraging Vivasure's PerQseal technology, the PerQseal Elite vascular closure system is designed exclusively for sutureless and fully absorbable large-bore closure follow

      4/22/25 9:36:00 AM ET
      $HAE
      $OBIO
      Medical/Dental Instruments
      Health Care
      Medicinal Chemicals and Botanical Products
    • Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025

      BOSTON, March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. The call can be accessed via teleconference at: Q4 2025 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call.

      3/31/25 4:00:00 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Leadership Updates

    Live Leadership Updates

    See more
    • Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

      SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

      9/24/24 8:00:00 AM ET
      $ALGS
      $HAE
      $NVO
      $PLRX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • Sotera Health Appoints Christopher Simon to the Board of Directors

      CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

      8/1/24 7:00:02 AM ET
      $HAE
      $SHC
      Medical/Dental Instruments
      Health Care
      Misc Health and Biotechnology Services
    • Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center

      BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the

      10/4/22 6:51:00 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Haemonetics Corporation

      SC 13G - HAEMONETICS CORP (0000313143) (Subject)

      11/14/24 1:28:29 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

      SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

      11/12/24 12:54:20 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

      SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

      11/8/24 10:41:07 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    SEC Filings

    See more
    • Haemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - HAEMONETICS CORP (0000313143) (Filer)

      5/8/25 6:03:40 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - HAEMONETICS CORP (0000313143) (Filer)

      3/3/25 4:13:00 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Haemonetics Corporation

      10-Q - HAEMONETICS CORP (0000313143) (Filer)

      2/6/25 6:20:48 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care

    $HAE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $HAE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Haemonetics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Haemonetics from Neutral to Underperform and set a new price target of $68.00 from $95.00 previously

      2/7/25 8:24:25 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Analyst initiated coverage on Haemonetics with a new price target

      Analyst initiated coverage of Haemonetics with a rating of Overweight and set a new price target of $116.00

      12/6/24 7:49:19 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • Haemonetics upgraded by Raymond James with a new price target

      Raymond James upgraded Haemonetics from Outperform to Strong Buy and set a new price target of $120.00

      11/8/24 7:51:25 AM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Financial Officer Darecca James covered exercise/tax liability with 654 shares, decreasing direct ownership by 4% to 16,692 units (SEC Form 4)

      4 - HAEMONETICS CORP (0000313143) (Issuer)

      5/5/25 4:16:09 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Chan Frank

      3 - HAEMONETICS CORP (0000313143) (Issuer)

      4/9/25 4:14:53 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care
    • President, Global Plasma & BC Galvin Roy covered exercise/tax liability with 161 shares, decreasing direct ownership by 2% to 7,373 units (SEC Form 4)

      4 - HAEMONETICS CORP (0000313143) (Issuer)

      11/5/24 4:17:29 PM ET
      $HAE
      Medical/Dental Instruments
      Health Care